Proton pump inhibitors (PPIs) have a major impact on gut microbiome and immune function which in turn, may increase the risk of inflammatory bowel disease (IBD). We undertake this study to evaluate PPI use and subsequent risk of IBD and subtypes (Crohn’s disease [CD] and ulcerative colitis [UC]).